ClinicalTrials.Veeva

Menu

Use of Wharton Jelly Derived Mesenchymal Stem Cells for Knee Osteoarthrosis

H

Hanan Jafar

Status and phase

Unknown
Phase 1

Conditions

Knee Osteoarthrosis

Treatments

Biological: Wharton Jelly derived mesenchymal stem cell

Study type

Interventional

Funder types

Other

Identifiers

NCT02963727
AlloKneeUJCTC

Details and patient eligibility

About

Wharton Jelly derived Mesenchymal Stem Cells (WJMSC) will be injected in patients diagnosed with Knee osteoarthrosis

Full description

Ten patients from both genders diagnosed with Knee osteoarthrosis, will be enrolled according to strict inclusion and exclusion criteria. These patients will be injected with Wharton Jelly derived Mesenchymal Stem Cells. Then, they are followed by clinical assessment, laboratory investigations as well as magnetic resonance imaging (MRI) of the injected knee.

Enrollment

10 estimated patients

Sex

All

Ages

42 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Severe KOA stage III or IV by Laurance & Kellgren staging as judged by Posterioranterior (PA) Xray of the knee joint.
  • Willing to participate by signing the informed consent

Exclusion criteria

  1. Sublaxation beyond 20 degrees of the bones of the knee joint
  2. Oral anticoagulants or heparin therapy
  3. Heart failure or arrhythmia
  4. Body Mass Index > 35
  5. Uncontrolled Diabetes Mellitus.
  6. Evidence of Infectious Diseases.
  7. Active infection
  8. Malignancy
  9. Pregnancy
  10. Anemia less than 11g/dl or thrombocytopenia less than 100,000 or leucopenia less than 3000.
  11. Unreliable patients
  12. Non-resident in Jordan

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

10 participants in 1 patient group

Wharton Jelly mesenchymal stem cell
Experimental group
Description:
Intra-articular Wharton Jelly derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of WJMSC in each dose
Treatment:
Biological: Wharton Jelly derived mesenchymal stem cell

Trial contacts and locations

1

Loading...

Central trial contact

Hanan Jafar, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems